<a href="https://laohu8.com/S/IOBT">IO Biotech</a> Announces Promising Results in Phase 3 Trial of Cylembio Plus KEYTRUDA for Advanced Melanoma, Plans FDA Meeting
IO Biotech Inc. has announced clinical improvement in progression-free survival demonstrated in a pivotal Phase 3 trial of Cylembio® combined with KEYTRUDA® (Pembrolizumab) for the treatment of first-line advanced melanoma. The results showed that patients treated with the combination therapy achieved an improvement in progression-free survival compared to those treated with pembrolizumab monotherapy, with a hazard ratio of 0.77 and a median progression-free survival of 19.4 months versus 11.0 months. However, the study's primary endpoint narrowly missed the statistical significance threshold. IO Biotech plans to discuss the data with the United States Food and Drug Administration this fall to determine next steps for submission of a Biologics License Application. The company also plans to present more detailed results from the IOB-013 study at a future medical meeting.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IO Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-177471), on August 11, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。